Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spiromustine: a new agent entering clinical trials.

D D Shoemaker, P J O'Dwyer, S Marsoni

    Investigational New Drugs
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Canadian Surgery Forum.

    Canadian journal of surgery. Journal canadien de chirurgie·2022
    Same author

    Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

    Canadian journal of surgery. Journal canadien de chirurgie·2022
    Same author

    Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

    NPJ precision oncology·2022
    Same author

    Long term outcome and elasticity of a polyester mesh used for laparoscopic ventral hernia repair.

    Hernia : the journal of hernias and abdominal wall surgery·2021
    Same author

    Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Subcutaneous and visceral adipose tissue in patients with primary and recurrent incisional hernia.

    Hernia : the journal of hernias and abdominal wall surgery·2021
    Same journal

    Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

    Investigational new drugs·2026
    Same journal

    Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

    Investigational new drugs·2026
    Same journal

    Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes.

    Investigational new drugs·2026
    Same journal

    Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.

    Investigational new drugs·2026
    Same journal

    Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.

    Investigational new drugs·2026
    Same journal

    Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330.

    Investigational new drugs·2026
    See all related articles

    Spiromustine, a novel lipophilic alkylating agent, shows promise for treating brain tumors and other cancers. Preclinical studies indicate efficacy and acceptable toxicity, leading to Phase I clinical trials.

    Area of Science:

    • Oncology
    • Pharmacology
    • Drug Development

    Background:

    • Spiromustine is a rationally designed, lipophilic alkylating agent.
    • Its lipophilicity facilitates central nervous system (CNS) penetration, suggesting potential for brain tumor treatment.
    • This property may also enhance activity against non-CNS tumors.

    Purpose of the Study:

    • To evaluate the preclinical efficacy and safety of spiromustine.
    • To characterize the pharmacokinetic and toxicological profile of spiromustine in animal models.

    Main Methods:

    • Preclinical screening against various tumor models, including intracranial ependymoblastoma.
    • Demonstration of alkylating activity in rat intracerebral glioma models.
    • Animal pharmacology studies to determine plasma decay, metabolism, and excretion.

    Related Experiment Videos

  • Toxicology studies in mice, rats, and dogs to identify dose-limiting toxicities.

    • Main Results:

    • Spiromustine demonstrated activity against a range of tumors, including brain tumors.
    • Pharmacology studies revealed a biphasic plasma decay, hepatic metabolism, enterohepatic circulation, and significant renal excretion of unchanged drug.
    • Toxicology studies identified dose-related myelosuppression and neurotoxicity as primary adverse effects, with other organ toxicities being mild.

    Conclusions:

    • Spiromustine exhibits preclinical efficacy against brain tumors and other malignancies.
    • The drug's pharmacokinetic and toxicological profiles suggest a manageable safety margin.
    • Spiromustine is advancing to Phase I clinical trials for further investigation.